Stock Earnings

Question 1

What are Stoke Therapeutics Inc's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Stoke Therapeutics Inc has a total asset of $272, Net loss of $-89

Question 2

What are the key financial ratios for STOK?

Accepted Answer

Stoke Therapeutics Inc's Current ratio is 6.32, has a Net margin is -247.22, sales per share of $0.66.

Question 3

How is Stoke Therapeutics Inc's revenue broken down by segment or geography?

Accepted Answer

Stoke Therapeutics Inc largest revenue segment is Antisense Oligonucleotide, at a revenue of 8,780,000 in the most earnings release.For geography, United States is the primary market for Stoke Therapeutics Inc, at a revenue of 8,780,000.

Question 4

Is Stoke Therapeutics Inc profitable?

Accepted Answer

no, according to the latest financial statements, Stoke Therapeutics Inc has a net loss of $-89

Question 5

Does Stoke Therapeutics Inc have any liabilities?

Accepted Answer

yes, Stoke Therapeutics Inc has liability of 43

Question 6

How many outstanding shares for Stoke Therapeutics Inc?

Accepted Answer

Stoke Therapeutics Inc has a total outstanding shares of 54

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	199	36	8	12	0	0
Revenue Growth (YoY)	1,227%	350%	-33%	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	56	49	41	38	31	20
Research & Development	104	89	82	77	54	32
Operating Expenses	159	138	124	116	86	53
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	55	-89	-105	-101	-85	-52
Income Tax Expense	1	--	--	--	--	--
Net Income	54	-89	-105	-101	-85	-52
Net Income Growth	-152%	-15%	4%	19%	63%	63%
Shares Outstanding (Diluted)	58	54	44	38.9	36.74	33.49
Shares Change (YoY)	4%	23%	13%	6%	10%	11%
EPS (Diluted)	0.93	-1.65	-2.38	-2.6	-2.34	-1.56
EPS Growth	-150%	-31%	-8%	11%	50%	46%
Free Cash Flow	60	-87	-82	-35	-68	-43
Free Cash Flow Per Share	1.03	-1.61	-1.86	-0.89	-1.85	-1.28
Gross Margin	--	--	--	--	--	--
Operating Margin	20.1%	-280.55%	-1,437.5%	-866.66%	0%	0%
Profit Margin	27.13%	-247.22%	-1,312.5%	-841.66%	0%	0%
Free Cash Flow Margin	30.15%	-241.66%	-1,025%	-291.66%	0%	0%
EBITDA	41	-99	-113	-103	-86	-53
EBITDA Margin	20.6%	-275%	-1,412.5%	-858.33%	0%	0%
D&A For EBITDA	1	2	2	1	0	0
EBIT	40	-101	-115	-104	-86	-53
EBIT Margin	20.1%	-280.55%	-1,437.5%	-866.66%	0%	0%
Effective Tax Rate	1.81%	--	--	--	--	--

Stoke Therapeutics Inc (STOK) Price

STOK Stock Price Chart

STOK Income

Follow-Up Questions